Skip to main content

Merck expects to sell $5 billion to $6 billion of its new Covid treatment pill in 2022

CEO Rob Davis said Merck is on track to fulfill its commitment in the coming days of delivering 3.1 million courses of its Covid treatment pill to the U.S.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.